NASDAQ:NVNO enVVeno Medical Q1 2026 Earnings Results & Report $8.75 +0.57 (+6.97%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$8.60 -0.15 (-1.71%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. enVVeno Medical beat analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$5.89 versus the -$8.40 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 7, 2026TimeAfter Market Closes enVVeno Medical EPS ResultsActual EPS-$5.89Consensus EPS -$8.40Beat/MissBeat by +$2.51One Year Ago EPSN/AEPS Beat Rate2 of last 5 quartersenVVeno Medical Revenue ResultsActual RevenueN/AExpected Revenue$0.50 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsenVVeno Medical's next earnings date is estimated for Friday, October 30, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile enVVeno Medical Q1 2026 Earnings FAQ Did enVVeno Medical beat earnings estimates for Q1 2026? enVVeno Medical (NASDAQ:NVNO) reported earnings of -$5.89 per share for Q1 2026, beating the consensus estimate of -$8.40. The report was announced on Thursday, May 7, 2026. When is enVVeno Medical's next earnings date? enVVeno Medical's next earnings date is estimated for Friday, October 30, 2026. MarketBeat tracks confirmed and estimated earnings dates for enVVeno Medical on the company's earnings history page. enVVeno Medical Earnings HeadlinesenVVeno Medical Corporation: enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal TrialOctober 2, 2026 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video SeriesSeptember 16, 2026 | finanznachrichten.deHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 10 at 1:00 AM | Banyan Hill Publishing (Ad)enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video SeriesSeptember 16, 2026 | finance.yahoo.comenVVeno Medical Corporation: enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-DemandSeptember 11, 2026 | finanznachrichten.deenVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand ConferenceAugust 27, 2026 | finance.yahoo.comSee More enVVeno Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enVVeno Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enVVeno Medical and other key companies, straight to your email. Email Address About enVVeno MedicalenVVeno Medical (NASDAQ:NVNO) (NASDAQ: NVNO) is a medical device company focused on developing bioprosthetic solutions for vascular and cardiovascular diseases. The company’s technologies are designed to address conditions for which existing medical and surgical treatments may be limited or ineffective. Its lead product candidate is the VenoValve, an investigational surgically implanted tissue-based valve intended to treat chronic deep venous insufficiency, including symptoms associated with post-thrombotic syndrome. The device is designed to help restore one-way blood flow in the deep veins of the leg and reduce venous hypertension. VenoValve has been evaluated in clinical studies and remains subject to regulatory review. enVVeno also has pursued transcatheter heart-valve technologies, including the enVVe system, which is intended to treat certain forms of tricuspid regurgitation. The company was formerly known as Hancock Jaffe Laboratories and adopted the enVVeno Medical name in 2021. It is headquartered in Nashville, Tennessee, and its products are in development and regulatory stages rather than broadly marketed commercial products.View enVVeno Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
